These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17909953)

  • 1. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.
    Berger M;
    J Clin Immunol; 2007 Nov; 27(6):628-33. PubMed ID: 17909953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
    Ballow M
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.
    Berger M; Pinciaro PJ; Althaus A; Ballow M; Chouksey A; Moy J; Ochs H; Stein M
    J Clin Immunol; 2010 Mar; 30(2):321-9. PubMed ID: 19997861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
    Berger M; Pinciaro PJ;
    J Clin Immunol; 2004 Jul; 24(4):389-96. PubMed ID: 15163895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
    Ochs HD; Pinciaro PJ;
    J Clin Immunol; 2004 May; 24(3):309-14. PubMed ID: 15114062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance study on the tolerability and safety of Flebogamma
    Alsina L; Mohr A; Montañés M; Oliver X; Martín E; Pons J; Drewe E; Papke J; Günther G; Chee R; Gompels M;
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
    Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
    Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.
    Jorquera JI
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):17-21. PubMed ID: 19630865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intravenous immunoglobulin (Flebogamma
    Apte S; Navarro-Puerto J; Damodar S; Ramanan V; John J; Kato G; Ross C; Shah C; Torres M; Fu C'; Rucker K; Pinciaro P; Barrera G; Aragonés ME; Ayguasanosa J
    Immunotherapy; 2019 Feb; 11(2):81-89. PubMed ID: 30499734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
    van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
    Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies.
    Kovaleva L; Apte S; Damodar S; Ramanan V; Loriya S; Navarro-Puerto J; Khojasteh A;
    Immunotherapy; 2016 Dec; 8(12):1371-1381. PubMed ID: 27817251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
    Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
    Kriván G; Borte M; Harris JB; Lumry WR; Aigner S; Lentze S; Staiger C
    Vox Sang; 2022 Oct; 117(10):1153-1162. PubMed ID: 35944615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
    Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
    Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.